Prostaglandin / insult

Dihydrogen phosphate salt of a prostaglandin D2 receptor antagonist

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

FIELD OF THE INVENTION Large-scale manufacturing of a pharmaceutical composition may pose many challenges to the chemist and chemical engineer. While many of these challenges relate to the handling of large quantities of reagents and control of large-scale reactions, the handling of the final

2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

FIELD OF THE INVENTION The present invention is directed to pyrimidine compounds, their preparation, pharmaceutical compositions containing these compounds, and their pharmaceutical use in the treatment of disease states capable of being modulated by the inhibition of prostaglandin D2

Methods for the use of inhibitors of cytosolic phospholipase A2

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

FIELD OF THE INVENTION The present invention relates to methods for the use of chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A.sub.2 enzymes (cPLA.sub.2), more particularly including inhibitors of cytosolic phospholipase A.sub.2 alpha

Methods for the use of inhibitors of cytosolic phospholipase A2

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

FIELD OF THE INVENTION The present invention relates to methods for the use of chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A.sub.2 enzymes (cPLA.sub.2), more particularly including inhibitors of cytosolic phospholipase A.sub.2 alpha

Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

TECHNICAL FIELD The present invention relates to (1) a carboxylic acid compound represented by formula (I) ##STR00002## wherein all symbols have the same meanings as follows, salts thereof, solvates thereof, and prodrugs thereof, (2) a process for producing the same, (3) a pharmaceutical composition

Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

TECHNICAL FIELD The present invention relates to (1) a carboxylic acid compound represented by formula (I) ##STR00002## wherein all symbols have the same meanings as follows, salts thereof, solvates thereof, and prodrugs thereof, (2) a process for producing the same, (3) a pharmaceutical composition

Thromboxane synthetase inhibiting 3-(1-alkenyl) pyridines

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

This invention relates to novel substituted vinyl derivatives which are capable of inhibiting thromboxane A.sub.2 (TXA.sub.2) synthetase specifically. TXA.sub.2 is one of the arachidonic acid metabolites and is a potent inducer of platelet aggregation and vascular smooth muscle contractions.

Vinyl carboxylic acid derivatives, their production and use as inhibitors of thromboxane synthetase

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

The present invention relates to novel substituted vinylcarboxylic acid derivatives which possess the action to inhibit specifically the thromboxane A.sub.2 (TXA.sub.2) synthetase. TXA.sub.2 is a metabolite of arachidonic acid and has the platelet aggregating action. Therefore, it has been known

Endogenous repair factor production accelerator

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

TECHNICAL FIELD The present invention relates to an endogenous repair factor production accelerator which comprises one or at least two selected from prostaglandin (hereinafter referred to as "PG") I2 agonist, EP2 agonist and EP4 agonist. BACKGROUND ART Regeneration medical treatment is drawing

Endogeneous repair factor production accelerators

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

TECHNICAL FIELD The present invention relates to an endogenous repair factor production accelerator which comprises one or at least two selected from prostaglandin (hereinafter referred to as "PG") I2 agonist, EP2 agonist and EP4 agonist. BACKGROUND ART Regeneration medical treatment is drawing

Endogeneous repair factor production promoters

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

TECHNICAL FIELD The present invention relates to an endogenous repair factor production accelerator which comprises one or at least two selected from prostaglandin (hereinafter referred to as "PG") I2 agonist, EP2 agonist and EP4 agonist. BACKGROUND ART Regeneration medical treatment is drawing

prostaglandin/insult

Dihydrogen phosphate salt of a prostaglandin D2 receptor antagonist

2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists

Methods for the use of inhibitors of cytosolic phospholipase A2

Methods for the use of inhibitors of cytosolic phospholipase A2

Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient

Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient

Thromboxane synthetase inhibiting 3-(1-alkenyl) pyridines

Vinyl carboxylic acid derivatives, their production and use as inhibitors of thromboxane synthetase

Endogenous repair factor production accelerator

Endogeneous repair factor production accelerators

Endogeneous repair factor production promoters

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus